Nano-X Imaging - Q1 2024

Transcript

Operator (participant)

Good day, and thank you for standing by. Welcome to Nanox First Quarter 2024 Earnings Conference Call. At this time, all participants on listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automatic message advising your hand is raised. As a reminder, this conference is being recorded. I would now like to send the call over to Mike Cavanagh of Investor Relations. Please go ahead.

Mike Cavanaugh (Head of Investor Relations)

Good morning, and thank you for joining us today. Earlier today, Nanox Imaging Limited released financial results for the quarter ended March 31st, 2024. The release is currently available on the investors section of the company's website. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host this morning's call. Before we get started, I would like to share some information with participants. First, if you're an institutional investor and would like to schedule a meeting with management or join an upcoming demonstration of the Nanox.ARC system, please contact me at [email protected], and we will work to schedule the requested meeting. Second, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing, commercialization activities, regulatory process operations, and other matters.

These statements are subject to risks, uncertainties, and assumptions that are based on management's current expectations as of today and may not be updated in the future. Therefore, these statements should not be relied upon as representing the company's views as of any subsequent date. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided with our press release, with the primary differences being non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, and non-GAAP gross loss per share.

With that, I'd now like to turn the call over to Erez Meltzer.

Erez Meltzer (CEO)

Thank you for joining us today, and as always, we appreciate your continuing support of Nanox and our mission as we strive for global health equity via innovation, particularly in medical technology and AI, which we believe is key and can directly impact patient outcomes. We aim to offer a comprehensive solution that connects medical imaging solutions from scan to diagnosis. During this call, we will provide updates on our strategic partnerships, product launches, and market expansions. We will also discuss our operational achievements. Our CFO, Ran Daniel, will present the financial highlights, and we will conclude with a Q&A session. We look forward to sharing our progress with you and answering questions you may have. Let's get started. We have kicked off 2024 with a positive momentum, achieving milestones in our U.S. commercialization work, strategic partnership, product launches, and market expansion outside the U.S.

In the first quarter of 2024, we've continued to make strides in our operational performance. Our key operational metrics reflect our commitment to excellence and our relentless pursuit of our mission to make medical imaging more accessible globally through innovative medical imaging technology. In the US, we are continuing with our installation plan. As of today, we have about 20 systems in the US, of which some have been installed and several more are in different stages of shipment and deployment. We have manufactured dozens of systems today, and we are confident that we can meet the accelerating demand for Nanox.ARC systems that we are seeing in the US market. Last month, we hosted an in-person live demonstration of the Nanox.ARC system on a patient as part of our investor event in Dynamic Medical Imaging in New Jersey.

Investors witnessed the entire patient scanning workflow with Nanox.ARC and observed the speed and precision of the generated images as well as for its clinical utility. Additionally, we presented samples from the undergoing chest clinical trial in Beilinson Hospital in Israel and outlined the path to expanded indications in the U.S. outside MSK. As the healthcare landscape continues to evolve, we are staying ahead of the curve by leveraging our cutting-edge technology and strategic partnerships. Per current installation, I can share that we recently received initial indication for reimbursement for Nanox.ARC as scan from a managed care insurance company. On a previous investor call, we discussed the building out-

of the support and service infrastructure Nanox.ARC users will need as deployment accelerates, specifically the Georgia site at 626 Imaging Academy, which serves as a technical and training center for technicians seeking to be trained on the use of the system. Anticipating the need for another vendor beyond 626 to provide installation services, as well as routine servicing of deployed Nanox.ARC systems, we have entered into a third-party agreement with Swissray. Located in Bridgewater, New Jersey, Swissray is one of the forefront experts in the area of digital radiography, from sales for installation, setup, training, and service. The agreement covers system installations, user support, troubleshooting, and regular system maintenance.

As we continue to expand our footprint on the ground in the U.S., we will constantly evaluate the need for commercial personnel to drive our growth, while also closely monitoring the need for service infrastructure to effectively support our advancements. Moreover, we have expanded the capabilities of our Nanox.ARC system with the addition of specialized MSK protocols, including protocols for cervical, thoracic, and lumbar spine. In addition to spine imaging, we have also fine-tuned our MSK protocols to include more detailed patient positioning options and further enhancement, which will aid healthcare providers in obtaining clearer and more accurate diagnostic images, facilitating better patient outcomes. These new protocols are designed to offer more precise and detailed imaging options, catering specifically to the needs of our customers based on feedback we have received from them.

Thanks to our advanced cloud-based ARC architecture, these upgrades have been implemented remotely across all systems without the need of physical modification or on-site visits. This approach significantly reduces service work hours and eliminates the need for travel, bringing efficiency and convenience to healthcare facilities. All upgrades have been meticulously performed in alignment with applicable regulatory requirements, ensuring our system continue to operate within their intended use and safety standards. We are confident that these upgrades will empower healthcare professionals further, elevate diagnosis capabilities, and enhance patient care in all facilities equipped with a Nanox.ARC system. Turning to our deployment efforts outside of the U.S. market, as previously mentioned, we continue to advance our commercial footprint in Africa, Latin America, and Asia. We have had a unit installed at the University of Ghana Medical Center, UGMC, and which has received local regulatory clearance.

We have had a footprint in Africa for some time and will continue to press our commercialization there. Furthermore, we are in the process of initiating a clinical trial at UGMC as part of our multi-site clinical trial. In Latin America, we continue to invest our commercial activities with respect to the Nanox.ARC and Nanox.CONNECT in Mexico, Peru, and Chile. At a high level, we will expand our geographic footprint as we achieve local regulatory authorizations. We also have Nanox.CONNECT operating system deployed in various countries, including Ghana, Morocco, Cameroon, and Israel. Some of these systems have been paid for upfront, which were referred to as CapEx model. Others are operating under the SaaS model, where we charge per scan, and some are currently being used for demonstration purposes.

In our quest to promote healthcare globally, we recently announced our entry in the South Korea market through our collaboration with AhealthZ, a healthcare distribution company, and SCL Science, AhealthZ affiliated company and subsidiary of Global Healthcare Group, SCL Bioclinic Laboratories. AhealthZ plans to assist Nanox in efforts to secure local authorization and licenses to enable the importation, marketing, and sales of the Nanox.ARC in South Korea, and will also include SCL Science integrating Nanox.AI solution. Additionally, Nanox Marketplace, a teleradiology services platform that provides remote access to radiology and cardiology experts, will potentially be integrated with SCL Science's teleradiology centers in South Korea and other overseas markets. This expansion is a testament to our ongoing efforts and our partners' commitment to bringing comprehensive medical imaging solutions to South Korea.

We hope the South Korea collaboration to be a stepping stone into the broader Southeast Asia market for the entire Nanox product suite. Turning to our important AI business segment, Nanox.AI recently signed two agreements. Covera Health, a leading healthcare technology company, has signed a multi-year contract with Nanox.AI to provide its three advanced AI solutions: cardiac, bone, and liver. Covera Health delivers clinically validated solutions for population health that improve patient outcomes, reduce healthcare costs, and enhance value-based care by supporting radiologists with technology capabilities that emphasizes improvement of quality and performance. Under this new agreement, Nanox will deploy the full suite of population health AI algorithms to support the needs of Covera's customers, and we will deploy the population health Nanox.AI algorithms, and for the first time, commercially installed HealthFLD.

HealthFLD aids clinicians in detecting fatty liver associated with metabolic dysfunction, associated steatotic liver diseases following FDA clearance last February. The second agreement is a collaboration with New York-based Dandelion Health, a healthcare data platform that focuses on AI analytics, offering healthcare providers accessibility to data with AI insights, and aims to bring products to market faster, providing a wealth of multi-mod, multi-model clinical data for healthcare pioneers. Clinical AI precision medi-medicine offer the potential for earlier diagnosis, personalized screening and prevention strategies, and more effective therapy. Dandelion Health partners with leading health systems to provide safe, ethical access to de-identified clinical data of unparalleled depth, quality, and diversity. Moving to developments in existing partnerships.

As part of our cooperation with Corewell, it was reported by Dr. Langholz, a cardiologist specialist, who participated in a Society of Cardiac CT webinar, that by using Nanox.AI cardiac solution, Corewell Health significantly increased their ability to detect coronary calcification, identifying nearly 4,000 new patients in 2023, compared to just 268 patients having CAC reported in the previous two years. This data demonstrates the effectiveness of the technology, but a great impact is the seamless integration into hospital electronic medical record systems, streamlining the process of incorporating these findings into patient records for improved care and management. On the regulatory front, Nanox.AI recently submitted to the FDA a new version of the cardiac AI solution, HealthCCSng, which introduces algorithm improvement aimed at enhancing accuracy and yield. It will also include new features that will improve coronary artery category detection accuracy.

We have also been busy integrating our acquisitions of the previous three years, deploying these assets to leverage our core platforms and technologies. One example is SecondOpinions.com, which we acquired through our USARAD subsidiary. SecondOpinions.com is an online medical platform providing second opinions in a wide variety of medical fields. This service is provided through the USARAD platform and has been available to patients since 2012. Nanox.AI functionality is being embedded in second opinions to allow private patients to use artificial intelligence to their second opinion CT reports, aiming to enhance the early detection of chronic conditions on chest and abdominal CT scans, with a short process of registration to the SecondOpinions.com website. The SecondOpinions.com service will provide access to the Nanox population health AI solutions that have already received FDA 510(k) clearance.

We expect the enhanced Second Opinions platform to be launched in a matter of weeks. Earlier this month, we announced that USARAD has once again earned the Joint Commission's Gold Seal of Approval for Ambulatory Healthcare Accreditation. The Joint Commission is a leading accrediting organization in the United States that certifies more than 22,000 healthcare organizations and programs based on the highest standard of patient safety and quality of care. Moving on to the production and OEM initiatives. As you know, we have entered into multiple supply agreements with prominent original equipment manufacturers around the world to ensure an adequate supply of high-quality components as we scale our manufacturing of the Nanox.ARC, and I will share an update on some of these. Our agreement with USA-based Varex to produce tubes is proceeding according to plan.

Tube design and development continues with the first prototype and Arc system integration, testing scheduled for this summer. In addition to tube development and manufacturing, we continue to explore additional opportunities together. Additionally, we continue to progress with other tube suppliers. We have produced and performed positive functional testing on our first wafers and chips developed in conjunction with Switzerland-based CSEM. We will build tubes with system chips in them for testing and validation in the coming weeks. We are transitioning our efforts toward process refinement, end-of-the-line testing, and planning for initial production wafer fabrication, second half of this year. Following up on our collaboration with the U.S. government agency, after their acquisition of our chips and tubes for evaluation, we have received a purchase order to collaborate on a novel tube development programs, potentially for non-invasive screening applications.

The initial phase of the design and simulation is underway, with component testing set to commence later this year. Our previously announced collaboration with a leading global medical technology company is also continuing as planned. We are still in the relatively early stages here, but I can share that they are now in the process of performing design and simulation for the purposes of finalizing a proposal, which would enable them to produce tubes for us. As part of their design and production simulation, they did purchase and test our chips, which allowed the Nanox team to meet them and their design team and their production facility in Europe. We will share updates as this collaboration moves toward a formal production agreement. We have identified our first few clients to take delivery of our demonstration kits.

As described, the Nanox demonstration kit, inclusive of Nanox chip, cold cathode tube, power supply, and the necessary software to operate the system, has been developed to expose potential partners to our technology and capabilities in a simplified manner. Now, I'd like to provide an update on the clinical aspect. Recognizing the fundamental clinical value of Nanox.ARC system to our future success, we devote substantial effort to conducting clinical trials and create clinical evidence for broader intended use. To date, we have three clinical trial sites: Shamir Medical Center in Israel, Beilinson Hospital, and the University of Ghana Medical Center (UGMC), and we are currently working to extend to a fourth facility, a prominent medical institution in Israel. In Ghana, the multicenter trial site is currently well-positioned to start soon. The trial has received local IRB approval and currently under the review of the Ghana FDA.

The Nanox.ARC system that will be used in the trial is now actively scanning patients. I would like also to share some real-world feedback on the value of Nanox technology. In a recent review with our clinical collaboration at Shamir Hospital and Beilinson Hospital in Israel, we have observed the significant impact our Nanox.ARC system can have on the daily routines of radiologists and referring clinicians. The Nanox.ARC system added valuable information to regular X-ray in almost all reviewed studies, showing excellent results for lung nodule detection, visualization of fractures that are hard to see on a standard radiograph, and accurate localization of fractures. We look forward to sharing these results with the clinical and scientific community at upcoming medical conferences. Speaking of Beilinson Hospital, the chest trial being run there is well underway.

We have already scanned more than a dozen chest patients, and initial results are promising. As I just mentioned, we hope to be able to share data from this study in some upcoming medical industry conferences. In addition, Beilinson has been formally integrated into the multicenter trial as the first site, and the trial is now actively recruiting, with additional referring departments are being added to the trial, mainly orthopedics and internal wards. I would like to take a moment to share that we have fortified our group of advisors and key opinion leaders with the addition of Dr. Greg Kicska. Dr. Kicska is a cardiothoracic radiologist with a Ph.D. in biochemistry. Dr. Kicska embarked on a career at the University of Washington in the cardiothoracic imaging division.

During his 12 years tenure at UW, he was awarded a grant from GE to study the clinical application of chest tomosynthesis. Dr. Kicska's clinical expertise included imaging diseases of the chest, heart, and blood vessels, with specialized training in cardiac MRI and cardiac CT. His research on digital tomosynthesis explore the unique advantages of these hybrid imaging methods. We are excited to welcome Dr. Kicska to the Nanox family and look forward to a productive collaboration. Turning to our regulatory efforts, we recently received an ISO 13485 certificate for the quality management system of the division from BSI. We completed this important step during the quarter as we continue to work with our notified body to secure CE Mark designation.

I believe the diverse area of development across multiple geographies and business segments I was able to share today underscore our commitment to making our innovative medical imaging technology accessible to healthcare providers and patients worldwide. In summary, the first quarter of 2024 has been a period of significant growth and progress for Nanox. We are excited about the opportunities ahead and look forward to sharing more updates in the coming months. I will now turn the call over to Ran Daniel, Chief Financial Officer.

Ran Daniel (CFO)

Thank you, Erez. We reported a GAAP net loss for the first quarter of 2024 of $12.2 million, which I'll refer to as the reported period, compared with a net loss of $11.8 million in the first quarter of 2023, which I'll refer to as the comparable period.

The increase was largely due to a one-time income that was recorded in the comparable period, due to a decrease in the company's earnout liabilities in the amount of $4.7 million, and a decrease in the gross profit in the amount of $0.5 million, which was offset by a decrease of $1.1 million in the research and development expenses, a decrease of $0.4 million in the sales and marketing expenses, $2.8 million in the general and administrative expenses, an increase of $0.4 million in the company's financial income.

Revenue for the reported period was $2.6 million, and gross loss was $2.0 million on a GAAP basis, compared to $2.4 million and a gross loss of $1.45 million on a GAAP basis for the comparable period. Non-GAAP gross profit for the reported period was $0.6 million, as compared to $1.0 million in the comparable period, which represents a gross profit margins of approximately 22% on a Non-GAAP basis for the reported period, as compared to 43% on a Non-GAAP basis in the comparable period.

Revenue from the teleradiology services for both the reported period and comparable period was $2.4 million, with a gross profit of $0.3 million on a GAAP basis in the reported period, as compared to a gross profit of $0.5 million on a GAAP basis in the comparable period, which represents a gross profit margin of approximately 14% on a GAAP basis for the reported period, as compared to 21% on a GAAP basis in the comparable period.

Non-GAAP gross profit of the company's teleradiology services for the reported period was $0.9 million, as compared to $1.1 million in the comparable period, which represents a gross profit margin of approximately 37% on a Non-GAAP basis for the reported period, as compared to 44% on a Non-GAAP basis in the comparable period. The decrease in the gross profit margins on a GAAP and Non-GAAP basis is mainly due to an increase in the cost of the company's radiologists due to the increase in the read rates during the overnight and weekend shift. During the reported period, the company generated revenue through the sales of its AI solutions in the amount of $97,000, as compared to revenue of $49,000 in the comparable period.

As noted previously, during the first quarter of 2024, Nanox.AI licensed its HealthCCSng cardiac solution to Intermountain Health for an annual fee of $8,500 during the first year of the engagement, and an annual fee of $75,000 from the first anniversary of the engagement and after. During the second quarter of 2024, Nanox.AI entered into a three-year contract to license its three advanced AI solutions, cardiac, bone, and liver, for an annual base fee of $50,000. During the reported period, the company generated revenue through the sales and deployment of its imaging systems, which amounted to $46,000, with a gross loss of $387,000 on a GAAP and Non-GAAP basis.

Those revenues stems from the sales and deployment of the Nanox.ARC system in the U.S. and the sales of our 2D systems in Africa. Research and development expenses for the reported period were $5.2 million, as compared to $6.3 million in the comparable period. The decrease of $1.1 million was mainly due to a research grant of $0.9 million that was received in connection with the NHSA project. Decrease of $0.2 million in salaries and wages, decrease of $0.2 million in share-based compensation, which was offset by an increase of $0.4 million in the expenses related to our research and development and regulatory activities. Sales and marketing expenses for the reported period were $0.8 million, as compared to $1.2 million in the comparable period.

The decrease was mainly due to a decrease in the expenses related to our sales and marketing activities. General and administrative expenses for the reported period were $5.0 million, as compared to $7.8 million in the comparable period. The decrease of $2.8 million was mainly due to a decrease in our legal expenses in the amount of $2.2 million, largely as a result of the finalization of the SEC investigation and the settlement of the class action, and a decrease in the cost of directors and officers' liability insurance premium in the amount of $0.4 million. Turning to our balance sheet.

As of March 31st, 2024, we had cash, cash equivalents, restricted deposits, and marketable securities of approximately $73.3 million, and a $3.3 million loan from a bank. We ended the first quarter of 2024 with a property and equipment net of $42.7 million. As of March 31st, 2024, we had approximately 57.8 million shares outstanding. With that, I will hand the call back over to Erez.

Erez Meltzer (CEO)

I want to thank you all once again for joining us on our call today, and your continued support of Nanox. As stated, the first quarter of 2024 was one of the strong commercial progress. This progress was not confined solely to the deployment of the Nanox.ARC system. We now have several CONNECT systems deployed, and some are generating revenues. Regarding Nanox.AI, we are proceeding with a pipeline of current and new product applications upgrades, continue to generate revenues, and gain adoption from healthcare providers worldwide. As always, we welcome your comments and are always available to meet with investors. Thanks again for your time today. That concludes our prepared remarks. Operator, please open the call for questions.

Operator (participant)

Thank you. Ladies and gentlemen, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, simply press star one one again. Please stand by while we compile the Q&A roster. Our first question coming from the lineup, Ross Osborne with Cantor Fitzgerald. Your line is open.

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Hi, guys. Thanks for taking our questions. So starting off, you mentioned 20 systems in the US in some stage of commercialization. How many of those were placed and being used during the quarter?

Erez Meltzer (CEO)

How many?

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Yes. Of the 20, I believe you said some had been imported, but not necessarily active. So just trying to, you know, update our model properly for the first quarter in terms of those 20 systems that were actually being used during the quarter.

Ran Daniel (CFO)

Yeah, Ross, answer your question, as of date, there are approximately 20 units. But as of March 31, we had already 13 of those, of those 20 already installed. So I hope that answers your question.

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Yes, that's very helpful. And then, regarding utilization-

Erez Meltzer (CEO)

Plus, maybe an additional point. Basically, this is making progress on an almost daily or weekly basis. We already mentioned that we have dozens in the sales pipeline, and, when I mean dozens, it's not one or two or three dozens, by far more. And, another point that could be mentioned that we are in fact installing today at one of the national radiology providers the first system. So, this is basically going forward on a weekly basis of being updated.

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Great. Glad to hear that, and very helpful as well. And then maybe just switching to the utilization levels. During the fourth quarter call, you were saying that you're seeing initial scans of about seven per day. Would you say that was consistent for the duration of the first quarter? And have you seen that uptick any?

Erez Meltzer (CEO)

Give and take, yeah. Yeah, but, but don't forget, it's too early to call. We're still in the midst of the soft launch, so we'll do all the conclusions, once we conclude this phase of the deployment.

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Okay.

Erez Meltzer (CEO)

One other indication that I'm referring to, items that I mentioned during the call, is that the more clinical protocols that we are adding, we see more scans per day. For example, the spine that we added, and the fact that we can do it online without the necessity to go to on site, and the fact that we have the initial reimbursement. Each one of these components, the clinical intended use, even sometimes the incidental findings that we have, that we talked about, and we'll talk further, these are each one of them is adding to the number of scans, more and more.

Ran Daniel (CFO)

Yeah. In essence, you can see that as a chain of reactions that starts from the clinical data that we accumulate and enhance and extend the commercial use of the machine.

Ross Osborn (Director and Lead Research Analyst for MedTech, Life Science Tools, and Diagnostics)

Got it. That makes perfect sense. Thanks for taking our questions, and congrats on progress.

Operator (participant)

Thank you. As a reminder, ladies and gentlemen, to ask a question, please press star one, one. Our next question coming from the line of Jeff Cohen with Ladenburg Thalmann. Your line is open.

Jeffrey Cohen (Director of Research and Managing Director)

Good morning, Erez. How are you?

Erez Meltzer (CEO)

Hi. Good morning, Jeff.

Jeffrey Cohen (Director of Research and Managing Director)

So, just a few questions on our end. I guess firstly, you talked about another two program. Could you elaborate a little further as far as your comment about it being non-invasive? Is it similar to your current platform, or what may be the difference?

Erez Meltzer (CEO)

I'm not sure I got the question. Are you referring about the tubes?

Jeffrey Cohen (Director of Research and Managing Director)

Yes.

Erez Meltzer (CEO)

It's about the tubes, yeah. So basically what we've indicated that we will have three suppliers for the tubes right now, and we may cooperate on other players in the future. The first one is, of course, what we do in South Korea. We spoke about the Italian tubes. We spoke about the future and intense and very broad cooperation that we have with Varex that we have already the final design. This will actually be a very broad technology breakthroughs that will come in the future. We always spoke about our OEM business.

We spoke about the US National Laboratory that we spoke about, and we spoke about another player in the medical imaging industry that might and have currently interest in our tubes. So, all of them basically are expanding our tube availability and tube installation in our systems.

Jeffrey Cohen (Director of Research and Managing Director)

Got it. Okay, nextly, could you talk about the second opinion service, and where or when you may launch that? And any specific data on that front would be helpful.

Erez Meltzer (CEO)

So, in fact, it's being used right now. We are extending these services to be available in other states. This is initially based on the technology and the platform that we have, first of all, integrated with the acquisition of the USARAD and the marketplace, MDW, that we did, and we build upon the availability of other players. So, right now it's operating, and we are planning to expand. It's generating revenues, and it's part of what USARAD offering, service offering, currently right now.

Jeffrey Cohen (Director of Research and Managing Director)

Got it. Okay, and then lastly-

Erez Meltzer (CEO)

It does not depend on the reimbursement. Yeah. And it's paid in cash. And we are adding the AI capabilities to these services as well.

Jeffrey Cohen (Director of Research and Managing Director)

Okay, got it. And then lastly for us, we've been doing some work on medical analytics regarding spine, skeletal, orthopedics. So could you talk about your platform versus CT straight up and the ability to transfer files directly into analytic software?

Erez Meltzer (CEO)

I'm not sure I got the question.

Jeffrey Cohen (Director of Research and Managing Director)

For a company that has an input of CTs versus Nanox imaging, could one be substituted for the other? And could you compare and contrast perhaps the capabilities among the skeletal system?

Erez Meltzer (CEO)

So, first of all, this is an area that we are going to elaborate more and more in the foreseeable, in the coming months. Because, based on the, based on the various clinical trials that we do and based on the, and the, first installations that we have, we gather a lot of, a lot of, clinical data. Based on this, as originally thought, and planned, what we would like to, to do is to be as close as the, as the, value that the CT is, providing. But more, but more and more, intended use or clinical, clinical evidence that, that we bring will be able to add value to the, the, to the users.

What we see right now is a lot, a lot of great indications that our offering can basically, we are in many ways changing standards of care, is something that we are adding value by far more than the X-ray, the regular X-ray is providing, but very close to the CT. And you know, we can talk about examples. Probably, we'll talk about it later, but the answer is definitely trying to do as much as we can with our equipment, it will enable to replace a lot of the CT intended use as we go forward.

Jeffrey Cohen (Director of Research and Managing Director)

Got it. Super helpful, and thanks for taking our questions.

Erez Meltzer (CEO)

Thank you. Thank you, Jeff.

Jeffrey Cohen (Director of Research and Managing Director)

Thank you, Jim.

Operator (participant)

Thank you. That is all the time we have for questions today. I will now hand the conference back to Mr. Erez Meltzer for any closing remarks.

Erez Meltzer (CEO)

Thank you all for making the time to listen to the progress that we have made. As you all know, we are putting a lot of efforts in three areas. Commercial, which we make a lot of progress and will continue to update as we move forward. One of the amazing findings or the progress that we made is something that we put a lot of effort and dedication, and this is the clinical evidence. This is coming from the clinical trials as well as the initial indications for the deployed systems. Last but not least, I would say a technology breakthrough that we are adding to the product roadmap to the future, a lot of the lessons learned from the process.

We are, of course, making all the necessary step in order to ensure that the regulatory will be the same, and to ensure that our promised premise that software, mainly AI and hardware, will be the basis of our conceptual offering from the end-to-end solution. I would say that every week we are making progress in even today we received a few new orders, an indication of the time that we're going to install the first system in Mexico is indicated. We received another purchase order from Philippines, so we are expanding on a global basis, and this will be something that will be shared as we move forward more and more. Thank you all, and have a great day.

Operator (participant)

This concludes today's conference. Thank you for your participation, and you may now disconnect.